Last Week Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings

June 27, 2018 - By Mary Bollinger

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
Big Money Sentiment decreased to 1.11 in 2018 Q1. It has change of 0.05, from 2017Q4’s 1.16. The ratio dived due to Regulus Therapeutics Inc. positioning: 8 sold and 10 reduced. 9 funds amassed holdings and 11 increased holdings. Investors holded 53.17 million in 2017Q4 but now own 50.71 million shares or 4.62% less.
Royal Bank Of Canada reported 146,607 shs. Blackrock Inc has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 780,792 shs. Fmr Limited Liability accumulated 15.59M shs. California Pub Employees Retirement Systems invested in 0% or 177,600 shs. Hightower Advisors Lc holds 0% or 22,475 shs in its capital. Drw Ltd Limited Liability Company reported 0.01% in Regulus Therapeutics Inc. (NASDAQ:RGLS). 737,995 were accumulated by Point72 Asset Management L P. Stratos Wealth Prtnrs Limited invested in 4,000 shs or 0% of the stock. 169,416 were accumulated by Art Advsr Ltd. Guggenheim Capital Limited Liability reported 0% stake. Geode Cap Mgmt Llc stated it has 483,951 shs or 0% of all its holdings. Two Sigma Secs Limited Liability Corp reported 18,963 shs or 0% of all its holdings. 384,538 are owned by Wells Fargo Co Mn. Macquarie Grp Limited invested in 0% or 20,000 shs. Brookstone Capital reported 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS).

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Total analysts of 5 have positions in Regulus Therapeutics (NASDAQ:RGLS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 40%. Since January 5, 2018 according to StockzIntelligence Inc Regulus Therapeutics has 7 analyst reports. On Thursday, February 8 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given by Wedbush. On Monday, March 12 the firm earned “Buy” rating by Wedbush. On Thursday, May 17 the rating was maintained by Wedbush with “Buy”. On Tuesday, March 27 the firm has “Hold” rating given by FBR Capital. In Thursday, March 8 report BMO Capital Markets maintained the stock with “Market Perform” rating. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

17/05/2018 Broker: Wedbush Rating: Buy New Target: $3.0000 Maintain
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On

RGLS is reaching $0.66 during the last trading session, after 0.60%.It’s downtrending since June 27, 2017 and is 45.33% down. RGLS underperformed by 57.90% the S&P500.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The firm is worth $68.85 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Currently it has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

There’s a substantial Regulus Therapeutics Inc. (NASDAQ:RGLS) news announced by It’s an article titled: “New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus …” on June 12, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.